• Home
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • 2.0 LPBI Brochure
  • Coronavirus, SARS-CoV-2 Portal
  • Knowledge PORTALS System (KPS)
  • Journal PharmaceuticalIntelligence.com
  • 2020-21 VISTA 1.0 LPBI
  • LPBI Group’s History
  • 2020-21 VISION – 2.0 LPBI
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder
  • Funding, Deals & Partnerships
  • LPBI Group News
  • CALENDAR
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2020 Summer Internship Portal
  • 2021 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • Blockchain Transactions Network Ecosystem
  • Contact Us
  • 1.0 LPBI Brochure

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Feeds:
Posts
Comments

PROTOCOL for LPBI Group’s Recruiting Strategy for R&D Scientists I,II,III and R&D Project Managers for Drug Discovery: Three Indications Considered

PROTOCOL for LPBI Group’s Recruiting Strategy for R&D Scientists I,II,III and R&D Project Managers for Drug Discovery: Three Indications Considered

Author: Aviva Lev-Ari, PhD, RN

 

Four Opportunities for PhDs, MDs, MD/PhDs, PharmDs

e-Mail your CV to: avivalev-ari@alum.berkeley.edu

The Process atLPBI Group involves the following steps:

 

#1: Skype interview with Scientist Candidate

  • Aviva
  • Gerard

#2: Scientist Candidate is invited to present to the Team

  • 60 minutes: FIVE Projects completed that yielded a Publication: Abstract and Reference for each project
  • 60 minutes: Scientist Candidate present the MAPPING of his set of skills onto the our MAP presented, below in MATERIALS TO BE REVIEWED by Scientist Candidates
  • 60 minutes: Group discussion on the above two presentations

#3: Candidate and the Team express interest in collaboration

  • Team agree to invite the Scientist Candidate to join the Team
  • Candidate e-mail request to receive our Admission Kit

#4: Candidate returns CV in MS Word and the FORM with 12 Declared Categories of Research

#5: We Grant Candidate ACCESS to the platform at “Author” privilege level on pharmaceuticalintelligence.com

#6: Candidate join the Weekly Team meetings on FRIDAYS at

9AM EST=6AM PST = 3PM Swiss Time = 4PM Israel Time

#7: Candidate submit a Project Proposal for funding R&D in CAR-T and TCRL for the Anti-Cancer Indication

#8: NewCo’s Management aggregated all Proposals into a MASTER R&D Plan for NewCo Drug Discovery effort in the three Indications to be performed by a SATELLITE of GLOBAL CANCER RESEARCHERS in their own Lab setting as PIs or in the NewCo facility in Boston, MA

Same process will be defined for the other two indications in the NewCo’s portfolio of Drug development in the Pipeline for 2016/2017.

  • Anti-inflammatory

Anti-Inflammatory MATERIALS TO BE REVIEWED by Scientist Candidates [to be added]

  • Diabetes

Diabetes MATERIALS TO BE REVIEWED by Scientist Candidates [to be added]

Four Opportunities for PhDs, MDs, MD/PhDs, PharmDs – Scientist Candidate will review the following opportunities withLPBI Group’ Virtual Team

 

  • Expert, Author, Writer (EAW) in the Journal 

Open Access Online Scientific Journal

Launched on 4/30/2012

http://pharmaceuticalintelligence.com

Site Statistics on 2/18/2016

Date

Views to Date

# of articles

NIH

Clicks

Nature Clicks

6/24/2013

199,857

1,034

1,275

661

 7/29/2013  217,356  1,138  1,389  705
       12/11/2013  293,694  1,464  1,693  828
10/17/2015  765,762  3,444  2,726 1,683 
02/18/2016  886,454 4,162  2,911 1,813 

https://pharmaceuticalintelligence.com/

  • Potential Co-Editorship on e-Books published on Amazon.com

https://pharmaceuticalintelligence.com/biomed-e-books/

  • Potential Author-Narrator on our Audio-Podcast Series in Medicine

https://pharmaceuticalintelligence.com/2016/01/25/launching-lpbis-fourth-line-of-business-d-five-podcast-audio-series-in-biomed/

All opportunities above are on Equity Sharing basis

– EAWs – per number of words published in the Journal,

– e-Book Editors are on 15% Royalties,

– BDs are Riders on my own Finder Fee Agreements in place

  • Potential involvement in Drug Discovery on Anti-Cancer – CAR–T and TCRL in a newly under formation Biotech Start up as Scientist I,II,III ot Project R&D Management

https://pharmaceuticalintelligence.com/gama-delta-epsilon-gde-is-a-global-holding-company-absorbing-lpbi/subsidiary-5-joint-ventures-for-ip-development-jvip/drug-discovery-with-3d-bioprinting/anti-cancer-car-t/

Start up will have employment opportunity for Scientist I,II,III and Project R&D Management positions per experience pending Funding secured to finance the Drug Discovery projects for the Three Indication, as above

Anti-Cancer MATERIALS TO BE REVIEWED by Scientist Candidates

For the Anti-Cancer Indication – Scientist Candidates will review the following links:

 

Immune-Oncology Molecules In Development & Articles on Topic in @pharmaceuticalintelligence.com

Curators: Stephen J Williams, PhD and Aviva Lev-Ari, PhD, RN

  • Cancer Biology & Genomics for Disease Diagnosis, on Amazon since 8/11/2015

http://www.amazon.com/dp/B013RVYR2K

  • Genomics Orientations for Personalized Medicine, on Amazon since 11/23/2015

http://www.amazon.com/dp/B018DHBUO6

  • Series C: e-Books on Cancer & Oncology

Volume 2: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery

  • Next-generation Universal Cell Immunotherapy startup Adicet Bio, Menlo Park, CA is launched with $51M Funding by OrbiMed
    Reporter: Aviva Lev-Ari, PhD, RN

 

Share this:

  • Twitter
  • Facebook
  • LinkedIn
  • Print
  • Email

Like this:

Like Loading...

  • Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 2,063 other followers

  • Recent Posts

    • National Resilience, Inc. is a first-of-its-kind manufacturing and technology company dedicated to broadening access to complex medicines and protecting biopharmaceutical supply chains against disruption – the Acquisition of Two Premier Biologics Manufacturing Facilities: Boston and in Ontario, Canada March 4, 2021
    • 19 of the 49 New Therapeutic Molecular Entities FDA approved in 2020 — as well as a new Cell-based therapy — are Personalized Medicines March 2, 2021
    • Happy 80th Birthday: Radioiodine (RAI) Theranostics: Collaboration between Physics and Medicine, the Utilization of Radionuclides to Diagnose and Treat: Radiation Dosimetry by Discoverer Dr. Saul Hertz, the early history of RAI in diagnosing and treating Thyroid diseases and Theranostics March 2, 2021
    • 2.0 LPBI is a Very Unique Organization  March 2, 2021
    • FDA emergency use authorization would bring the public a third vaccine for the novel coronavirus – J&J single vaccine – Authorized on 2/28/2021 March 1, 2021
    • Medical Device Representatives coach Surgeons in the Operating Rooms March 1, 2021
    • 2021 Virtual World Medical Innovation Forum, Mass General Brigham, Gene and Cell Therapy, VIRTUAL May 19–21, 2021 February 26, 2021
    • Inhibitory CD161 receptor recognized as a potential immunotherapy target in glioma-infiltrating T cells by single-cell analysis February 20, 2021
    • First single-course ‘curative’ CRISPR Shot by Intellia rivals Alnylam, Ionis and Pfizer February 19, 2021
    • Contribution of Nervous System Functional Deterioration to late-life Mortality: The Role Neurofilament light chain (NfL) a Blood Biomarker for the Progression of Neurological Diseases and its Correlation to Age and Life Expectancy February 19, 2021
  • Archives

  • Categories

  • Meta

    • Register
    • Log in
    • Entries feed
    • Comments feed
    • WordPress.com
    • 2012pharmaceutical
    • Amandeep Kaur
    • Aashir Awan, Phd
    • Adina Hazan
    • Alan F. Kaul, PharmD., MS, MBA, FCCP
    • alexcrystal6
    • anamikasarkar
    • apreconasia
    • aviralvatsa
    • David Orchard-Webb, PhD
    • danutdaagmailcom
    • Demet Sag, Ph.D., CRA, GCP
    • Daniel Menzin
    • Dror Nir
    • dsmolyar
    • evelinacohn
    • Gail S Thornton
    • Irina Robu
    • jayzmit48
    • jdpmd
    • jshertok
    • kellyperlman
    • Ed Kislauskis
    • larryhbern
    • Madison Davis
    • marzankhan
    • megbaker58
    • ofermar2020
    • Dr. Pati
    • pkandala
    • Rosalind Codrington, PhD
    • ritusaxena
    • Rick Mandahl
    • sjwilliamspa
    • stuartlpbi
    • Dr. Sudipta Saha
    • tildabarliya
    • zraviv06
    • zs22

Blog at WordPress.com.

WPThemes.


loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
%d bloggers like this: